Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

The microbiome and cancer for clinicians.

Picardo SL, Coburn B, Hansen AR.

Crit Rev Oncol Hematol. 2019 Jun 8;141:1-12. doi: 10.1016/j.critrevonc.2019.06.004. [Epub ahead of print] Review.

PMID:
31202124
2.

Aryl hydrocarbon receptor agonist indigo protects against obesity-related insulin resistance through modulation of intestinal and metabolic tissue immunity.

Lin YH, Luck H, Khan S, Schneeberger PHH, Tsai S, Clemente-Casares X, Lei H, Leu YL, Chan YT, Chen HY, Yang SH, Coburn B, Winer S, Winer DA.

Int J Obes (Lond). 2019 Apr 3. doi: 10.1038/s41366-019-0340-1. [Epub ahead of print]

PMID:
30944419
3.

Mycobiome Sequencing and Analysis Applied to Fungal Community Profiling of the Lower Respiratory Tract During Fungal Pathogenesis.

McTaggart LR, Copeland JK, Surendra A, Wang PW, Husain S, Coburn B, Guttman DS, Kus JV.

Front Microbiol. 2019 Mar 15;10:512. doi: 10.3389/fmicb.2019.00512. eCollection 2019.

4.

Comparing Patient Risk Factor-, Sequence Type-, and Resistance Locus Identification-Based Approaches for Predicting Antibiotic Resistance in Escherichia coli Bloodstream Infections.

MacFadden DR, Melano RG, Coburn B, Tijet N, Hanage WP, Daneman N.

J Clin Microbiol. 2019 May 24;57(6). pii: e01780-18. doi: 10.1128/JCM.01780-18. Print 2019 Jun.

5.

Microbiome networks and change-point analysis reveal key community changes associated with cystic fibrosis pulmonary exacerbations.

Layeghifard M, Li H, Wang PW, Donaldson SL, Coburn B, Clark ST, Caballero JD, Zhang Y, Tullis DE, Yau YCW, Waters V, Hwang DM, Guttman DS.

NPJ Biofilms Microbiomes. 2019 Jan 21;5:4. doi: 10.1038/s41522-018-0077-y. eCollection 2019.

6.

Penicillin-binding protein 3 is a common adaptive target among Pseudomonas aeruginosa isolates from adult cystic fibrosis patients treated with ╬▓-lactams.

Clark ST, Sinha U, Zhang Y, Wang PW, Donaldson SL, Coburn B, Waters VJ, Yau YCW, Tullis DE, Guttman DS, Hwang DM.

Int J Antimicrob Agents. 2019 May;53(5):620-628. doi: 10.1016/j.ijantimicag.2019.01.009. Epub 2019 Jan 19.

PMID:
30664925
7.

A genome-wide association analysis reveals a potential role for recombination in the evolution of antimicrobial resistance in Burkholderia multivorans.

Diaz Caballero J, Clark ST, Wang PW, Donaldson SL, Coburn B, Tullis DE, Yau YCW, Waters VJ, Hwang DM, Guttman DS.

PLoS Pathog. 2018 Dec 7;14(12):e1007453. doi: 10.1371/journal.ppat.1007453. eCollection 2018 Dec.

8.

Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized Trial.

Mikuls TR, Cheetham TC, Levy GD, Rashid N, Kerimian A, Low KJ, Coburn BW, Redden DT, Saag KG, Foster PJ, Chen L, R Curtis J.

Am J Med. 2019 Mar;132(3):354-361. doi: 10.1016/j.amjmed.2018.11.011. Epub 2018 Nov 29.

PMID:
30503879
9.

Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma.

Oliva M, Spreafico A, Taberna M, Alemany L, Coburn B, Mesia R, Siu LL.

Ann Oncol. 2019 Jan 1;30(1):57-67. doi: 10.1093/annonc/mdy507.

10.

Off-target effects of tribendimidine, tribendimidine plus ivermectin, tribendimidine plus oxantel-pamoate, and albendazole plus oxantel-pamoate on the human gut microbiota.

Schneeberger PHH, Coulibaly JT, Gueuning M, Moser W, Coburn B, Frey JE, Keiser J.

Int J Parasitol Drugs Drug Resist. 2018 Dec;8(3):372-378. doi: 10.1016/j.ijpddr.2018.07.001. Epub 2018 Jul 2.

11.

Rectal and Naris Swabs: Practical and Informative Samples for Analyzing the Microbiota of Critically Ill Patients.

Bansal S, Nguyen JP, Leligdowicz A, Zhang Y, Kain KC, Ricciuto DR, Coburn B.

mSphere. 2018 Jun 13;3(3). pii: e00219-18. doi: 10.1128/mSphere.00219-18.

12.

Reply.

Coburn BW, Michaud K, Bergman DA, Mikuls TR.

Arthritis Rheumatol. 2018 Oct;70(10):1697-1698. doi: 10.1002/art.40549. Epub 2018 Aug 23. No abstract available.

PMID:
29740984
13.

Decision-support models for empiric antibiotic selection in Gram-negative bloodstream infections.

MacFadden DR, Coburn B, Shah N, Robicsek A, Savage R, Elligsen M, Daneman N.

Clin Microbiol Infect. 2019 Jan;25(1):108.e1-108.e7. doi: 10.1016/j.cmi.2018.03.029. Epub 2018 Apr 25.

PMID:
29705558
14.

Regional variability in fecal microbiota transplantation practices: a survey of the Southern Ontario Fecal Microbiota Transplantation Movement.

Hota SS, Surangiwala S, Paterson AS, Coburn B, Poutanen SM; Southern Ontario Fecal Microbiota Transplantation (SOFT) Movement*.

CMAJ Open. 2018 Apr 18;6(2):E184-E190. doi: 10.9778/cmajo.20170109.

15.

Re: The impact of antibiotics on the Intestinal microbiota needs to be re-defined in order to optimize the antibiotic usage; by Ruppe et al.

Coburn B, Daneman N, MacFadden DR, Rooney A.

Clin Microbiol Infect. 2018 Jul;24(7):783-784. doi: 10.1016/j.cmi.2018.03.021. Epub 2018 Mar 30. No abstract available.

PMID:
29608966
16.

Early detection using qPCR of Pseudomonas aeruginosa infection in children with cystic fibrosis undergoing eradication treatment.

Blanchard AC, Rooney AM, Yau Y, Zhang Y, Stapleton PJ, Horton E, Klingel M, Stanojevic S, Ratjen F, Coburn B, Waters V.

J Cyst Fibros. 2018 Nov;17(6):723-728. doi: 10.1016/j.jcf.2018.02.008. Epub 2018 Mar 7.

PMID:
29525410
17.

Allopurinol Dose Escalation and Mortality Among Patients With Gout: A National Propensity-Matched Cohort Study.

Coburn BW, Michaud K, Bergman DA, Mikuls TR.

Arthritis Rheumatol. 2018 Aug;70(8):1298-1307. doi: 10.1002/art.40486. Epub 2018 Jul 8.

PMID:
29513934
18.

7 versus 14 days of antibiotic treatment for critically ill patients with bloodstream infection: a pilot randomized clinical trial.

Daneman N, Rishu AH, Pinto R, Aslanian P, Bagshaw SM, Carignan A, Charbonney E, Coburn B, Cook DJ, Detsky ME, Dodek P, Hall R, Kumar A, Lamontagne F, Lauzier F, Marshall JC, Martin CM, McIntyre L, Muscedere J, Reynolds S, Sligl W, Stelfox HT, Wilcox ME, Fowler RA; Canadian Critical Care Trials Group.

Trials. 2018 Feb 17;19(1):111. doi: 10.1186/s13063-018-2474-1.

19.

Optimizing Empiric Antibiotic Selection in Sepsis: Turning Probabilities Into Practice.

MacFadden DR, Daneman N, Coburn B.

Clin Infect Dis. 2018 Jan 18;66(3):479. doi: 10.1093/cid/cix775. No abstract available.

PMID:
29020208
20.

Allopurinol Medication Adherence as a Mediator of Optimal Outcomes in Gout Management.

Coburn BW, Bendlin KA, Sayles H, Meza J, Russell CL, Mikuls TR.

J Clin Rheumatol. 2017 Sep;23(6):317-323. doi: 10.1097/RHU.0000000000000561.

PMID:
28816767
21.

Utility of prior cultures in predicting antibiotic resistance of bloodstream infections due to Gram-negative pathogens: a multicentre observational cohort study.

MacFadden DR, Coburn B, Shah N, Robicsek A, Savage R, Elligsen M, Daneman N.

Clin Microbiol Infect. 2018 May;24(5):493-499. doi: 10.1016/j.cmi.2017.07.032. Epub 2017 Aug 12.

22.

Response to comment on "Using geospatial mapping to design HIV elimination strategies for sub-Saharan Africa".

Okano JT, Coburn BJ, Blower S.

Sci Transl Med. 2017 Aug 2;9(401). pii: eaan8494. doi: 10.1126/scitranslmed.aan8494.

23.

Using geospatial mapping to design HIV elimination strategies for sub-Saharan Africa.

Coburn BJ, Okano JT, Blower S.

Sci Transl Med. 2017 Mar 29;9(383). pii: eaag0019. doi: 10.1126/scitranslmed.aag0019.

24.

Benefits and unintended consequences of antimicrobial de-escalation: Implications for stewardship programs.

Hughes J, Huo X, Falk L, Hurford A, Lan K, Coburn B, Morris A, Wu J.

PLoS One. 2017 Feb 9;12(2):e0171218. doi: 10.1371/journal.pone.0171218. eCollection 2017.

25.

Oral Vancomycin Followed by Fecal Transplantation Versus Tapering Oral Vancomycin Treatment for Recurrent Clostridium difficile Infection: An Open-Label, Randomized Controlled Trial.

Hota SS, Sales V, Tomlinson G, Salpeter MJ, McGeer A, Coburn B, Guttman DS, Low DE, Poutanen SM.

Clin Infect Dis. 2017 Feb 1;64(3):265-271. doi: 10.1093/cid/ciw731. Epub 2016 Nov 9.

PMID:
28011612
26.

The Problem with Gout Is That It's Still Such a Problem.

Coburn BW, Mikuls TR.

J Rheumatol. 2016 Aug;43(8):1453-5. doi: 10.3899/jrheum.160614. Review. No abstract available.

PMID:
27481987
27.

Rationale and design of the randomized evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-UP) Study.

Coburn BW, Cheetham TC, Rashid N, Chang JM, Levy GD, Kerimian A, Low KJ, Redden DT, Bridges SL Jr, Saag KG, Curtis JR, Mikuls TR.

Contemp Clin Trials. 2016 Sep;50:106-15. doi: 10.1016/j.cct.2016.07.019. Epub 2016 Jul 20.

28.

Can Probiotics Reduce Inflammation and Enhance Gut Immune Health in People Living with HIV: Study Designs for the Probiotic Visbiome for Inflammation and Translocation (PROOV IT) Pilot Trials.

Kim CJ, Walmsley SL, Raboud JM, Kovacs C, Coburn B, Rousseau R, Reinhard R, Rosenes R, Kaul R.

HIV Clin Trials. 2016 Jul;17(4):147-57. doi: 10.1080/15284336.2016.1184827. Epub 2016 Jun 7.

PMID:
27267710
29.

Target Serum Urate: Do Gout Patients Know Their Goal?

Coburn BW, Bendlin KA, Sayles H, Hentzen KS, Hrdy MM, Mikuls TR.

Arthritis Care Res (Hoboken). 2016 Jul;68(7):1028-35. doi: 10.1002/acr.22785.

30.

Treatment Options for Acute Gout.

Coburn BW, Mikuls TR.

Fed Pract. 2016 Jan;33(1):35-40.

31.

Chronic infection phenotypes of Pseudomonas aeruginosa are associated with failure of eradication in children with cystic fibrosis.

Vidya P, Smith L, Beaudoin T, Yau YC, Clark S, Coburn B, Guttman DS, Hwang DM, Waters V.

Eur J Clin Microbiol Infect Dis. 2016 Jan;35(1):67-74.

PMID:
26492874
32.

Selective Sweeps and Parallel Pathoadaptation Drive Pseudomonas aeruginosa Evolution in the Cystic Fibrosis Lung.

Diaz Caballero J, Clark ST, Coburn B, Zhang Y, Wang PW, Donaldson SL, Tullis DE, Yau YC, Waters VJ, Hwang DM, Guttman DS.

MBio. 2015 Sep 1;6(5):e00981-15. doi: 10.1128/mBio.00981-15.

33.

Phenotypic diversity within a Pseudomonas aeruginosa population infecting an adult with cystic fibrosis.

Clark ST, Diaz Caballero J, Cheang M, Coburn B, Wang PW, Donaldson SL, Zhang Y, Liu M, Keshavjee S, Yau YC, Waters VJ, Elizabeth Tullis D, Guttman DS, Hwang DM.

Sci Rep. 2015 Jun 5;5:10932. doi: 10.1038/srep10932.

34.

The human microbiome.

Coburn B, Guttman DS.

CMAJ. 2015 Aug 11;187(11):825. doi: 10.1503/cmaj.141072. Epub 2015 May 19. Review. No abstract available.

35.

Lung microbiota across age and disease stage in cystic fibrosis.

Coburn B, Wang PW, Diaz Caballero J, Clark ST, Brahma V, Donaldson S, Zhang Y, Surendra A, Gong Y, Elizabeth Tullis D, Yau YC, Waters VJ, Hwang DM, Guttman DS.

Sci Rep. 2015 May 14;5:10241. doi: 10.1038/srep10241.

36.

Point prevalence survey of antimicrobial utilization in a Canadian tertiary-care teaching hospital.

Lee C, Walker SA, Daneman N, Elligsen M, Palmay L, Coburn B, Simor A.

J Epidemiol Glob Health. 2015 Jun;5(2):143-50. doi: 10.1016/j.jegh.2014.06.003. Epub 2014 Aug 8.

37.

Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system.

Rashid N, Coburn BW, Wu YL, Cheetham TC, Curtis JR, Saag KG, Mikuls TR.

J Rheumatol. 2015 Mar;42(3):504-12. doi: 10.3899/jrheum.140588. Epub 2014 Dec 15.

38.

Vancomycin-variable enterococci can give rise to constitutive resistance during antibiotic therapy.

Thaker MN, Kalan L, Waglechner N, Eshaghi A, Patel SN, Poutanen S, Willey B, Coburn B, McGeer A, Low DE, Wright GD.

Antimicrob Agents Chemother. 2015 Mar;59(3):1405-10. doi: 10.1128/AAC.04490-14. Epub 2014 Dec 15.

39.

Maximising the effect of combination HIV prevention in Kenya.

Blower S, Coburn BJ.

Lancet. 2014 Oct 18;384(9952):1426. doi: 10.1016/S0140-6736(14)61859-6. Epub 2014 Oct 17. No abstract available.

PMID:
25390322
40.

Performance of self-reported measures for periodontitis in rheumatoid arthritis and osteoarthritis.

Coburn BW, Sayles HR, Payne JB, Redman RS, Markt JC, Beatty MW, Griffiths GR, McGowan DJ, Mikuls TR.

J Periodontol. 2015 Jan;86(1):16-26. doi: 10.1902/jop.2014.140339.

PMID:
25269524
41.

Mapping HIV epidemics in sub-Saharan Africa with use of GPS data.

Coburn BJ, Blower S.

Lancet Glob Health. 2013 Nov;1(5):e251-3. doi: 10.1016/S2214-109X(13)70084-6. Epub 2013 Oct 24. No abstract available.

42.

Vancomycin-variable Enterococcus faecium: in vivo emergence of vancomycin resistance in a vancomycin-susceptible isolate.

Coburn B, Low DE, Patel SN, Poutanen SM, Shahinas D, Eshaghi A, Willey BM, McGeer A.

J Clin Microbiol. 2014 May;52(5):1766-7. doi: 10.1128/JCM.03579-13. Epub 2014 Feb 12.

43.

Predicting the potential for within-flight transmission and global dissemination of MERS.

Coburn BJ, Blower S.

Lancet Infect Dis. 2014 Feb;14(2):99. doi: 10.1016/S1473-3099(13)70358-X. No abstract available. Erratum in: Lancet Infect Dis. 2015 Aug;15(8):875.

PMID:
24457166
44.

Increasing survival time decreases the cost-effectiveness of using "test & treat'' to eliminate HIV epidemics.

Wagner BG, Coburn BJ, Blower S.

Math Biosci Eng. 2013 Oct-Dec;10(5-6):1673-86. doi: 10.3934/mbe.2013.10.1673.

45.

Current drivers and geographic patterns of HIV in Lesotho: implications for treatment and prevention in Sub-Saharan Africa.

Coburn BJ, Okano JT, Blower S.

BMC Med. 2013 Oct 16;11:224. doi: 10.1186/1741-7015-11-224.

46.

Antimicrobial susceptibilities of clinical isolates of HACEK organisms.

Coburn B, Toye B, Rawte P, Jamieson FB, Farrell DJ, Patel SN.

Antimicrob Agents Chemother. 2013 Apr;57(4):1989-91. doi: 10.1128/AAC.00111-13. Epub 2013 Feb 12.

47.

Blood culture collection for suspected bacteremia--reply.

Coburn B, Morris AM, Detsky AS.

JAMA. 2013 Jan 23;309(4):339. doi: 10.1001/jama.2012.113524. No abstract available.

PMID:
23340624
48.

Does this adult patient with suspected bacteremia require blood cultures?

Coburn B, Morris AM, Tomlinson G, Detsky AS.

JAMA. 2012 Aug 1;308(5):502-11. doi: 10.1001/jama.2012.8262. Review. Erratum in: JAMA. 2013 Jan 23;309(4):343.

PMID:
22851117
50.

Modeling the impact on the HIV epidemic of treating discordant couples with antiretrovirals to prevent transmission.

El-Sadr WM, Coburn BJ, Blower S.

AIDS. 2011 Nov 28;25(18):2295-9. doi: 10.1097/QAD.0b013e32834c4c22.

Supplemental Content

Loading ...
Support Center